These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32899553)

  • 1. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents.
    Calafiore V; Giamporcaro S; Conticello C; Romano A; Parisi M; Giuffrida G; Tibullo D; Di Raimondo F; Signorelli SS
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
    Morabito F; Zamagni E; Conticello C; Pavone V; Palmieri S; Bringhen S; Galli M; Mangiacavalli S; Derudas D; Rossi E; Ria R; Catalano L; Tacchetti P; Mele G; Vincelli ID; Martino EA; Vigna E; Bruzzese A; Mendicino F; Botta C; Mele A; Pantani L; Rocchi S; Garibaldi B; Cascavilla N; Ballanti S; Tripepi G; Frigeri F; Falcone AP; Cangialosi C; Reddiconto G; Farina G; Barone M; Rizzello I; Iaccino E; Mimmi S; Curci P; Gamberi B; Musto P; De Stefano V; Musso M; Petrucci MT; Offidani M; Di Raimondo F; Boccadoro M; Cavo M; Neri A; Gentile M
    Front Oncol; 2022; 12():890376. PubMed ID: 35924160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
    Morabito F; Zamagni E; Conticello C; Pavone V; Palmieri S; Bringhen S; Galli M; Mangiacavalli S; Derudas D; Rossi E; Ria R; Catalano L; Tacchetti P; Mele G; Donatella Vincelli I; Antonia Martino E; Vigna E; Botta C; Bruzzese A; Mele A; Pantani L; Rocchi S; Garibaldi B; Cascavilla N; Ballanti S; Tripepi G; Frigeri F; Pia Falcone A; Cangialosi C; Reddiconto G; Farina G; Barone M; Rizzello I; Musto P; De Stefano V; Musso M; Teresa Petrucci M; Offidani M; Neri A; Di Renzo N; Di Raimondo F; Boccadoro M; Cavo M; Gentile M
    Eur J Haematol; 2022 Mar; 108(3):178-189. PubMed ID: 34716957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Al-Ani F; Bermejo JM; Mateos MV; Louzada M
    Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
    Loncharich AJ; Fiala MA; Slade MJ; Vickroy A; Kavanaugh M; Wilson C; Schroeder MA; Stockerl-Goldstein K; Vij R; Sanfilippo KM
    Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):825-828. PubMed ID: 37543510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
    Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).
    Liu J; Yang H; Liang X; Wang Y; Hou J; Liu Y; Wang J; Zhou F
    Oncotarget; 2017 Sep; 8(37):62435-62444. PubMed ID: 28977957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
    Shin J; Lee JJ; Kim K; Min CK; Lee JO; Suh C; Kim JS; Lee YJ; Yoon SS; Jo JC; Lee HS; Bang SM;
    Int J Hematol; 2019 Jan; 109(1):79-90. PubMed ID: 30291558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel.
    Leleu X; Katodritou E; Kuehr T; Terpos E; Caers J; Zambello R; Brescianini A; Liang T; Wetten S; Badelita SN
    EJHaem; 2023 Feb; 4(1):174-183. PubMed ID: 36819146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a
    Wang J; Park C; Arroyo-Suarez R
    Leuk Lymphoma; 2021 Sep; 62(9):2219-2226. PubMed ID: 33836624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
    Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
    Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
    Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide.
    Engelhardt M; Ajayi S; Reinhardt H; Müller SJ; Dold SM; Wäsch R
    Recent Results Cancer Res; 2018; 212():169-185. PubMed ID: 30069630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
    Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
    Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
    Li Q; Zhang B; Cheng Q; Zhao F; Li J; Yan H; Xu A; Sun C; Hu Y
    Ann Med; 2023; 55(2):2263019. PubMed ID: 37983471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.